Results 41 to 50 of about 313,244 (194)

AN OVERVIEW: IMMUNOTOXIN

open access: yes, 2021
Immunotoxins are hybrid molecules composed of a monoclonal antibody chemically linked to a biologic toxin. The antibody portion of the molecule directs it to a specific antigenic determinant on a target cell; the molecule is then internalized, and a ...
Blessy M.R*, Subash Chandran M.P, Prasobh G.R, Remya S.B, Aparna P, Rohini L M, Varsha V R, Archana L R
core   +1 more source

Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer

open access: yesToxins, 2016
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, yet no effective therapeutics exist. This review provides an overview of the recent development of recombinant immunotoxins for the treatment of glypican-3 (GPC3) expressing ...
Bryan D. Fleming, Mitchell Ho
doaj   +1 more source

Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin

open access: yes
A colorectal tumour-directed immunotoxin, ICI D0490, has been constructed by linking recombinant ricin A-chain to C242, a mouse monoclonal antibody, by means of a methyl-hindered disulphide bond. Recombinant ricin A-chain and a hindered disulphide linker
Calvete JA   +3 more
core   +5 more sources

Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval

open access: yesBlood Advances, 2019
: Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog.
Adam Yuh Lin, Shira Naomi Dinner
doaj   +1 more source

Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology [PDF]

open access: yes, 2020
Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors.
Hurtado-Guerrero, Ramón   +14 more
core   +1 more source

Recombinant immunotoxins development for HER2-based targeted cancer therapies

open access: yesCancer Cell International, 2021
Understanding the molecular mechanisms of cancer biology introduces targeted therapy as a complementary method along with other conventional therapies. Recombinant immunotoxins are tumor specific antibodies that their recognizing fragment is utilized for
Reza Mahmoudi   +6 more
doaj   +1 more source

Intrahippocampal Adeno-Associated Virus–Mediated Overexpression of Nerve Growth Factor Reverses 192IgG-Saporin–Induced Impairments of Hippocampal Plasticity and Behavior

open access: yesFrontiers in Neuroscience, 2021
One of the aspects of Alzheimer disease is loss of cholinergic neurons in the basal forebrain, which leads to development of cognitive impairment.
Yulia V. Dobryakova   +6 more
doaj   +1 more source

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

open access: yesToxins, 2016
Recombinant immunotoxins (RITs) are fusions of an Fv-based targeting moiety and a toxin. Pseudomonas exotoxin A (PE) has been used to make several immunotoxins that have been evaluated in clinical trials.
Gilad Kaplan   +6 more
doaj   +1 more source

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

open access: yesHaematologica, 2023
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation model of IgD+ lymphocyte-predominant cells by Moraxella catarrhalis antigen RpoC and ...
Lorenz Thurner   +26 more
doaj   +1 more source

Bispecific human IL2‐CCR4 immunotoxin targets human cutaneous T‐cell lymphoma

open access: yesMolecular Oncology, 2020
The majority of clinically diagnosed cutaneous T‐cell lymphomas (CTCL) highly express the cell‐surface markers CC chemokine receptor 4 (CCR4) and/or CD25.
Haoyu Wang   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy